Literature DB >> 22365608

A bacterial lipooligosaccharide that naturally mimics the epitope of the HIV-neutralizing antibody 2G12 as a template for vaccine design.

Brenda E Clark1, Kate Auyeung, Eleonora Fregolino, Michelangelo Parrilli, Rosa Lanzetta, Cristina De Castro, Ralph Pantophlet.   

Abstract

The broadly neutralizing antibody 2G12 binds a fairly conserved cluster of oligomannose sugars on the HIV surface glycoprotein gp120, which has led to the hypothesis that these sugars pose potential vaccine targets. Here, we present the chemical analysis, antigenicity, and immunogenicity of a bacterial lipooligosaccharide (LOS) comprised of a manno-oligosaccharide sequence analogous to the 2G12 epitope. Antigenic similarity of the LOS to oligomannose was evidenced by 2G12 binding to the LOS and the inability of sera elicited against synthetic oligomannosides, but incapable of binding natural oligomannose, to bind the LOS. Immunization with heat-killed bacteria yielded epitope-specific serum antibodies with the capacity to bind soluble gp120. Although these sera did not exhibit specific anti-HIV activity, our data suggest that this LOS may find utility as a template for the design of glycoconjugates to target HIV.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22365608     DOI: 10.1016/j.chembiol.2011.12.019

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  18 in total

Review 1.  Recent strategies targeting HIV glycans in vaccine design.

Authors:  Satoru Horiya; Iain S MacPherson; Isaac J Krauss
Journal:  Nat Chem Biol       Date:  2014-12       Impact factor: 15.040

2.  Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans.

Authors:  Hong Zhang; Hu Fu; Robert J Luallen; Bingfen Liu; Fang-Hua Lee; Robert W Doms; Yu Geng
Journal:  Vaccine       Date:  2015-08-13       Impact factor: 3.641

3.  Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose.

Authors:  Robyn L Stanfield; Cristina De Castro; Alberto M Marzaioli; Ian A Wilson; Ralph Pantophlet
Journal:  Glycobiology       Date:  2014-11-07       Impact factor: 4.313

Review 4.  Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.

Authors:  Laurent Verkoczy
Journal:  Adv Immunol       Date:  2017       Impact factor: 3.543

Review 5.  Multivalent glycoconjugates as anti-pathogenic agents.

Authors:  Anna Bernardi; Jesus Jiménez-Barbero; Alessandro Casnati; Cristina De Castro; Tamis Darbre; Franck Fieschi; Jukka Finne; Horst Funken; Karl-Erich Jaeger; Martina Lahmann; Thisbe K Lindhorst; Marco Marradi; Paul Messner; Antonio Molinaro; Paul V Murphy; Cristina Nativi; Stefan Oscarson; Soledad Penadés; Francesco Peri; Roland J Pieters; Olivier Renaudet; Jean-Louis Reymond; Barbara Richichi; Javier Rojo; Francesco Sansone; Christina Schäffer; W Bruce Turnbull; Trinidad Velasco-Torrijos; Sébastien Vidal; Stéphane Vincent; Tom Wennekes; Han Zuilhof; Anne Imberty
Journal:  Chem Soc Rev       Date:  2012-12-19       Impact factor: 54.564

6.  2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies.

Authors:  Katie J Doores; Michael Huber; Khoa M Le; Sheng-Kai Wang; Colleen Doyle-Cooper; Anthony Cooper; Ralph Pantophlet; Chi-Huey Wong; David Nemazee; Dennis R Burton
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

7.  Directed evolution of 2G12-targeted nonamannose glycoclusters by SELMA.

Authors:  J Sebastian Temme; Michael G Drzyzga; Iain S MacPherson; Isaac J Krauss
Journal:  Chemistry       Date:  2013-11-13       Impact factor: 5.236

8.  A glycoside analog of mammalian oligomannose formulated with a TLR4-stimulating adjuvant elicits HIV-1 cross-reactive antibodies.

Authors:  Jean-François Bruxelle; Tess Kirilenko; Nino Trattnig; Yiqiu Yang; Matteo Cattin; Paul Kosma; Ralph Pantophlet
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

9.  Synthetic Neoglycoconjugates of Hepta- and Nonamannoside Ligands for Eliciting Oligomannose-Specific HIV-1-Neutralizing Antibodies.

Authors:  Matteo Cattin; Jean-François Bruxelle; Kurtis Ng; Markus Blaukopf; Ralph Pantophlet; Paul Kosma
Journal:  Chembiochem       Date:  2022-02-11       Impact factor: 3.461

10.  High-throughput profiling of anti-glycan humoral responses to SIV vaccination and challenge.

Authors:  Christopher T Campbell; Sean R Llewellyn; Thorsten Demberg; Thorsten Damberg; Ian L Morgan; Marjorie Robert-Guroff; Jeffrey C Gildersleeve
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.